Antiemetics And Antinauseants Market Performance and Future Outlook at 13.8% CAGR Through 2029

Uncover key drivers, emerging technologies, and competitive movements shaping the antiemetics and antinauseants market from 2025–2034 with trusted insights from The Business Research Company

What Is The Predicted Size Of The Antiemetics And Antinauseants Industry By 2029?

The peptide based metabolic disorders therapeutics market size has experienced rapid growth in recent years. It is forecast to expand from $29.89 billion in 2024 to $34.1 billion in 2025, progressing at a compound annual growth rate (CAGR) of 14.1%. This historic growth can be ascribed to factors such as the increasing prevalence of metabolic disorders, advancements in peptide synthesis technologies, rising healthcare expenditure, a growing aging population, an expanding biopharmaceutical sector, regulatory approvals for new therapies, and increasing awareness about personalized medicine.

The peptide based metabolic disorders therapeutics market size is anticipated to undergo significant expansion in the coming years, with projections indicating a rise to $57.13 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 13.8%. This foreseen growth during the forecast period can be attributed to several factors such as the innovation in peptide analogs, increased investments in research and development for metabolic disorders, the implementation of precision medicine strategies, the widening scope of emerging markets, collaborative efforts and partnerships in drug creation, progress in delivery technologies, and a focus on patient-centric therapies. Notable trends within the forecast period encompass the deployment of artificial intelligence in drug discovery, the expansion of personalized treatments, the use of CRISPR/Cas9 for genetic therapies, the integration of wearable devices for patient monitoring, the formulation of oral peptide medications, the increasing prevalence of digital therapeutics in disease management, and the growth of biobanking for tailored therapeutic interventions.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16764&type=smp

What Major Drivers Are Impacting The Antiemetics And Antinauseants Market?

The increasing incidence of obesity is projected to propel the expansion of the peptide-based metabolic disorders therapeutic market in the future. Obesity, a medical condition marked by an excessive buildup of body fat that poses health hazards, is becoming more prevalent due to factors such as inactive lifestyles, unhealthy eating habits, genetic predispositions, and environmental influences that promote calorie-rich diets and physical inactivity. Peptide-based metabolic disorders therapeutics work by harnessing peptides to regulate metabolic functions, enhance insulin sensitivity, and control appetite, thereby improving patient health outcomes and mitigating the long-term health risks associated with these chronic conditions, including obesity. For instance, data from The British Diabetic Association, a UK-based healthcare professional and research charity, indicated that in April 2024, 4.4 million people in the UK were living with diabetes, with an additional estimated 1.2 million potentially having undiagnosed type 2 diabetes. Furthermore, the 2022-23 registration figures demonstrated an increase of 167,822 cases from 2021-22. Therefore, the rising prevalence of obesity is a key driver for the peptide-based metabolic disorder therapeutics market.

Which Segment Categories Are Driving Maximum Growth In The Antiemetics And Antinauseants Market?

The peptide based metabolic disorders therapeutics market covered in this report is segmented –

1) By Drug Type: Liraglutide, Exenatide, Other Drug Type

2) By Application: Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Other Applications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Liraglutide: Brand: Saxenda, Brand: Victoza, Generic Liraglutide, Liraglutide For Type 2 Diabetes, Liraglutide For Obesity

2) By Exenatide: Brand: Byetta, Brand: Bydureon, Exenatide For Type 2 Diabetes, Extended-Release Exenatide, Generic Exenatide

3) By Other Drug Type: Semaglutide, Dulaglutide, Albiglutide, Lixisenatide, GLP-1 Receptor Agonists, Pramlintide, Other Peptide-Based Drugs For Metabolic Disorders

Which Long-Term Trends Will Play A Crucial Role In The Antiemetics And Antinauseants Market?

Major companies in the peptide-based metabolic disorders therapeutics market are creating innovative peptide-based treatments, such as anti-diabetic biosimilars, to address medical needs that are not yet met and to broaden patient treatment options. Peptide-based anti-diabetic biosimilars refer to therapeutic medications that imitate existing peptide-based diabetes therapies, providing comparable effectiveness and safety profiles to established drugs, while potentially lowering treatment costs via competitive pricing. For instance, in January 2024, Glenmark Pharmaceuticals Ltd., an India-based pharmaceutical company, launched Lirafit in India, which is a biosimilar version of the popular anti-diabetic drug Liraglutide. It belongs to the category of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). This class of medications imitates the action of the naturally occurring GLP-1 hormone, which is vital for controlling blood sugar levels. This biosimilar has undergone clinical trials, proving its efficacy in reducing glycemic parameters, promoting weight loss, and enhancing cardiovascular safety. These are essential advantages for managing diabetes and related conditions like obesity and cardiovascular diseases.

Who Are The Dominant Players In The Antiemetics And Antinauseants Market Today?

Major companies operating in the peptide based metabolic disorders therapeutics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Eli Lilly Company, Amgen Inc., Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Jazz Pharmaceuticals plc, Ipsen S.A, BioMarin Pharmaceutical Inc., Amarin Corporation plc, PolyPeptide Group

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/peptide-based-metabolic-disorders-therapeutics-global-market-report

Which Region Is At The Forefront Of Innovation In The Antiemetics And Antinauseants Market?

North America was the largest region in the peptide based metabolic disorders therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide based metabolic disorders therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=16764&type=smp

Browse Through More Reports Similar to the Global Antiemetics And Antinauseants Market 2025, By The Business Research Company

Microbiome Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/microbiome-therapeutics-global-market-report

Neurodegenerative Disorder Therapeutic Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

Antisense And Rnai Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795